Docoh
Loading...

76 results

Filter options loading...
Top filers
Top filing types
Recent filing years
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
studies and clinical trials, and our research and development programs; our ability to retain the continued service of our key professionals … intend to use the net proceeds for general corporate purposes, which may include conducting clinical trials, research and development activities
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
13 Aug 21
Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
6:16am
million as of December 31, 2020 and we had 15.6 million shares of common stock outstanding as of August 2, 2021. Our research and development expenses
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
(Unaudited) Three Months Ended Six Months Ended June 30, Operating Expenses Research and development expenses Acquisition of in-process research … activities: Depreciation Non-cash lease expense for right-of-use assets Non-cash acquisition of in-process research and development Amortization of debt
S-3
PCSA Processa Pharmaceuticals Inc
30 Jun 21
Shelf registration
4:02pm
, if approved; the initiation, timing, progress and results of our pre-clinical studies and clinical trials, and our research and development programs; our … will be used for general corporate purposes, which may include conducting clinical trials, research and development activities, working capital, capital
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
13 May 21
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
5:28pm
research and development expenses for the three months ended March 31, 2021 were $1.5 million compared to $501 thousand for the three months ended March 31 … , regulatory approvals, expected research and development costs, planned preclinical studies and clinical trials, expected results of clinical trials
10-Q
k5ysujl
13 May 21
Quarterly report
4:30pm
DEF 14A
o0to 4i4e76e62e7va
22 Apr 21
Definitive proxy
2:00pm
424B3
m7gprpzg1gx5n 2g7
12 Apr 21
Prospectus supplement
1:44pm
10-K/A
gbn0bcvksj
7 Apr 21
Annual report (amended)
4:23pm
S-3
xlwz9m
1 Apr 21
Shelf registration
8:00pm
10-K
ftzbzem yks9
24 Mar 21
Annual report
8:00pm
8-K
EX-99.1
tu4ay2 tlz
24 Mar 21
Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update
8:00pm
10-Q
mdxtk1
12 Nov 20
Quarterly report
4:01pm
424B4
z94gillnuogcnxlkbb
5 Oct 20
Prospectus supplement with pricing info
4:16pm
S-1/A
zn7ktr zo6
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
m1btsx7tryb8jvd gam7
16 Sep 20
IPO registration (amended)
8:00pm
10-Q
bcx1pva5xbp39
5 Aug 20
Quarterly report
3:32pm
S-1/A
anufly
17 Jul 20
IPO registration (amended)
5:25pm
10-Q
zsy83e1q mndau
15 May 20
Quarterly report
1:23pm
10-K
e8u7cl6z
5 Mar 20
Annual report
7:00pm